DEFYMED France

DEFYMED Defymed is a french startup that develops implantable bio-artificial medical devices for cell therapy with a first focus on type 1 diabetes Industry sectors Medtech Therapeutics Area Endocrinology
Your innovative solution

The initial product designed is a bioartificial Pancreas, named MAILPAN

Which problem are you solving ?

MAILPAN

Target market segments

Market segment 1: type 1 diabets/ Market segment 2: liver diseases

Key value proposition

Advantage 1: functioning autonomy due to its physiologic implantation site/ Advantage 2: Entry and exit ports allowing filling/emptying of cells when needed/ Advantage 3: Big volume, which allows filling with a sufficient number of cells/ Advantage 4: flat surface allowing to maximise surface exchanges and cells survival and function 

Dr Richard BOUAOUN
Dr Richard BOUAOUN
Director of Operations 

Eukarys France

Innovative non-viral non-integrative gene therapy and DNA vaccination for treatment of severe human diseases based on proprietary set of expression technologies

Philippe JAIS
CEO, CSO 

Eurobio France

Eurobio Eurobio has a European-leading expertise in research, diagnostics, and corneal conservation and transportation in cold storage and organ culture. Industry sectors BioPharma Therapeutics Area Ophthalmology
Your innovative solution

iGlide and the Cornea range bring innovative lamellar conservation and transportation solutions that make the corneal graft easier, quicker and more flexible. The cornea is trephined and pre-cut in the eye bank. Lamellar membrane is placed in the iGlide, conserved in the medium and sent to the physician.

Which problem are you solving ?

iGlide saves time during surgeries, and isn

Target market segments

1/ Eye banks 2/ Other tissue brokers 3/ Surgeons 4/ Hospitals - GPO

Key value proposition

1/ non invasive 2/ inexpensive 3/ no learning curve for surgeon 4/ Best quality for the eye banks and physicians

Denis Fortier
CEO 

FEELIGREEN France

FEELIGREEN Feeligreen is a technology startup developing safe and effective micro-current devices for a wide range of dermo-therapeutic applications. Industry sectors Medtech Therapeutics Area Dermatology
Rheumatology
Your innovative solution

We incorporate semiconductor, microelectronics, bio-electronic and drug-formulation innovations into a technology platform from which we are already prototyping products that leap forward with unprecedented safety, ease-of-use and efficiency. Our initial in-vitro results demonstrate an ability to improve transdermic drug delivery by 4 to 10x on a large range of molecules.

Which problem are you solving ?

Targeted medical applications range from prevention of bedsores to controlled pain-relief and wound healing. Combined with advanced photo-dynamic therapy, we develop advanced solutions for dermatology. Our total addressable market is estimated to reach $7 billion by 2018.

Target market segments

Dermatology (psoriasis, atopic demartitis, labial herpes, acne, alopecia, ...) ; Pain relief (chronic pain, BTP, neuropathic and arthritic pain) ; Bedsores (bedsore prevention, bedsore detection , chronic wounds)

Key value proposition

Security and Safety / Controlled Drug Delivery / Programmable-Remote bolus / Measure of compliance

Dr CHRISTOPHE BIANCHI
Dr CHRISTOPHE BIANCHI
CEO 

FIRALIS France

Firalis  Firalis offers a wide spectrum of biomarker services from discovery to the clinical qualification Industry sectors Biotech Therapeutics Area Cardiology / Vascular Diseases
Rare Disease
Rheumatology
Your innovative solution

Firalis has developed an integrated platform in its own laboratory located in Huningue, France. The platform includes a clinical testing laboratory, an assay development laboratory and a production site for critical reagents. The company is striving to develop bioanalytical tools such as antibodies, assay kits or microarrays that are meeting the highest standards of quality. The process leading to the design and production of these products is compliant with ISO 13485 standards, the international norm for medical devices

Which problem are you solving ?

With a comprehensive expertise in the field, Firalis develops biomarkers and biomarker-based diagnostic kits to improve disease outcomes, patient comfort and therapeutic decisions; finally to generate remarkable savings in healthcare, which is the principal goal of biomarker services offered by Firalis. Our activities mainly but not exclusively involve biomarkers that are related to inflammatory disorders including common diseases such as atherosclerosis, rheumatoid arthritis or rare/orphan diseases such as systemic or autoimmune vasculitis

Target market segments

The services consist of biomarker R&D programs for clients such as pharmaceutical companies, biotechnology companies and public laboratories.

Key value proposition

Novel values via biomarkers, discovery, cutting-edge platform, high quality standard

TONY YAACOUB
CHIEF BUSINESS OFFICER 

GLOBAL CARE Initiative France

GLOBAL CARE Initiative is a French consortium of five non-profit Carnot research institutes dedicated to human health.

CALYM, the Consortium for the acceleration of innovation and its transfer to the field of Lymphoma
Curie Cancer, a component of Institut Curie focused on cancers
ICM, the Brain and Spine Institute dedicated to CNS diseases
Pasteur MI, the infectious diseases division of the Institut Pasteur
Voir et Entendre, expert in vision and audition diseases and rehabilitation

Our goal is to operate as a one-stop shop to life sciences companies and research and technological organizations that seek effective R&D partnerships. The Carnot Institutes can collaborate at any stage — from basic research to late clinical phases. GLOBAL CARE Initiative combines strong scientific expertise to unique technology platforms to propose an innovation-centered collaboration offer.

Specialties

CNS Diseases, Vision and Audition Diseases, Cancers, Lymphoma, Infectious Diseases

GLOBAL CARE Initiative GLOBAL CARE Initiative is a consortium of 5 French leading research institutes focused on infectious diseases (The institut Pasteur), oncology (The institut Curie), lymphoma (CALYM), vision and audition diseases (Voir et Entendre) and CNS (The brain and spine institute). Industry sectors All Therapeutics Area CNS-Neurology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Oncology
Ophthalmology
Rare Disease
Your innovative solution

The institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other RTOs.

Which problem are you solving ?

The consortium operates as a one-stop-shop for life science companies and research organizations that seek R&D collaboration from basic research to the late clinical phases

Target market segments

Basic research / Preclinical research / Clinical

Key value proposition

One stop shop for all of the insitutes / Translational research collaborations (biobanks-clinical data/trials - Epidemiologic data - Animal/cells models) / Access to European market (Patient population/Cormecial market/ European KOLs/clinical centers)/New sourcing for innovation

Anne-Cécile Peras
USA East Coast Development 
Mr Etienne Bendjebbar
USA West Coast Development 

Graftys France

Graftys Graftys specializes in bone tissue engineering; we design, manufacture and sell innovative synthetic calcium phosphate bone graft substitutes. Industry sectors Biotech Therapeutics Area Orthopedics/Orthopedic Surgery
Your innovative solution

1) Developement of patented injectable resorbable biomaterials which harden in situ, allowing minimally invasive surgery and are quickly resorbed by the cellular activity and replaced by natural bone. 2) Design and development of combinaison devices utilizing synthetic bone substitute materials and therapeutic agents as well as autologous tissue which will address such clinical challenges as prevention of osteoporotic fractures, prevention of infection and enhanced bone ingrowth

Which problem are you solving ?

1) Bone defect filling via MIS techniques for younger patients; 2) "Super-Fast" resorption and remodeling to boost bone reconstruction for non union management; 3) Local treatment or prevention of osteoporotic patient ; 4) management of bone Infection by our innovative calcium phosphate cement combined with antibiotic (exposed trauma, military application...)

Target market segments

1) Orthopaedic: Trauma and Reconstruction; 2) Spine Surgery; 3)Dentistry

Key value proposition

1) Patented technology which provides unique soluctions to address key clinical needs; 2) Proprietary pipeline of innovative bone tissue engineering solutions; 3) Fully integrated organization and facilities which include R&D, manufacturing, regulatory, sales and marketing; 4) Strong relationships with leading global orthopedic companies; 5) years of very successful sales and clinical experience in 23 countries of the world

Emilie Ostaszuk
Marketing Manager 

H4D France

H4D H4D provides easy and convenient access to a physician through a connected telehealth kiosk, the Consult Station, supported by a best-in-class technology platform. Industry sectors E health Therapeutics Area Cardiology / Vascular Diseases
Dermatology
Infectious Diseases - Vaccines
Nutrition and Weight Loss
Ophthalmology
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Psychiatry/Psychology
Your innovative solution

The Consult Station

Which problem are you solving ?

Access to care is an increasing challenge throughout the world at a time when chronic diseases, an ageing population and increasing costs challenge current medical organizations. H4D

Target market segments

Corporations, hospitals, retirement communities, rural and remote areas.

Key value proposition

1) Quality and certification for professional medical use, 2) Large functional coverage for primary care uses, 3) Convenient and easy access to a physician, 4) Cost savings.

VINCENT HILLENMEYER
COO 

HARMONIC PHARMA France

THE COMPANY

Finding new uses of safe drugs based on polypharmacology profiling: Armonco® a clinical candidate for lung cancer.

OBJECTIVES FOR THIS EVENT

Harmonic Pharma is looking for a company which would be interested in acquiring the exclusive license of Armonco® in order to perform its clinical development in lung cancer.

TECHNOLOGY AND PRODUCTS

Harmonic Pharma has developed a unique and innovative know-how combining polypharmacology with relevant animal models mimicking human diseases. This expertise has been applied to identify a clinical candidate for lung cancer from existing safe drugs:  Armonco® has been developed to be licensed out for a clinical trial.

KEY ADVANTAGES

New targeted therapy for lung cancer

Armonco® acting in monotherapy and in combination with existing treatments including inhibitor antibodies

Clinical candidate with already well documented safety in man

Cost-effective process and shortening time to market

Consolidated IP including a specific formulation

Ø  Seeking companies interested in discussing common business opportunities in the cancer area

Arnaud Sinan KARABOGA
Arnaud Sinan KARABOGA
CSO 

Hemarina SA France

Hemarina Hemarina : A breakthrough in oxygen carriers for human health. Industry sectors Biotech Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Gastroenterology / Hepatology
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Pulmonary/Respiratory Diseases
Rare Disease
Your innovative solution

Hemarina develops products that constitute a decisive technological breakthrough in regard to current or past developments of hemoglobin-based oxygen carriers (HBOCs).

Which problem are you solving ?

HEMOXYcarrier� = Universal oxygen carrier (Lack of blood worldwide is ~ 100 millions liters per year) - HEMO2Life : Organ & Tissue preservation - HEMHealing : Wound Healing & Repair

Target market segments

1/ Blood Oxygen Transporter, 2/ Organ & Tissue preservation, 3/ /Wound Healing & Repair

Key value proposition

1/ Unique know how from development to production of oxygen carriers 2/ Strong academic network & partnerships 3/ Broad intellectual property covering Hemarina's technology 4/ international publications

Franck Zal
CEO